New Points of Departure for More Global Influenza Vaccine Use

Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the dru...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2020-07, Vol.8 (3), p.410
Main Author: Kiseleva, Irina
Format: Article
Language:English
Subjects:
COVID-19
cross protectivity
Deoxyribonucleic acid
DNA
Drug resistance
Eggs
Genomes
inactivated vaccines
Infections
Influenza
Licenses
live attenuated vaccines
Manufacturers
Manufacturing
Mutation
Nanoparticles
next-generation vaccines
Pandemics
Peptides
Prevention
Prophylaxis
Proteins
Public health
Respiratory diseases
Severe acute respiratory syndrome coronavirus 2
synthetic vaccines
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines8030410